Arkolith/Insider Trading/TAK/Form 4

Furuta Milano

Chief Financial Officer, DirectorTAKEDA PHARMACEUTICAL CO LTD (TAK) · full profile →Form 4 · filed Jul 6, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
1 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 1, 2026Grant(A)12K—$070K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jul 1, 2026Disposed to issuer(D)17K$4931.50$82.0M0
Jul 1, 2026Grant(A)4K—$012K
Jul 1, 2026Grant(A)4K—$08K
Jul 1, 2026Grant(A)4K—$04K

Transaction Codes

A
Grant / award
D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001395064-26-000260) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML